Literature DB >> 10850728

Nerve growth factor treatment in dementia.

M E Jönhagen1.   

Abstract

Millions of people are affected by Alzheimer disease. As longevity increases, so will the number of patients with dementia. This has led to an intense search for successful treatment strategies. One area of interest is neurotrophic factors. Brain development and neuronal maintenance, as well as protective efforts, are mediated by a large number of different neurotrophic factors acting on specific receptors. In neurodegenerative disorders, there may be a possibility of rescuing degenerating neurons and stimulating terminal outgrowth with use of neurotrophic factors. The first neurotrophic factor discovered was nerve growth factor (NGF). A wealth of animal studies have shown that cholinergic neurons are NGF sensitive and NGF dependent, which is especially interesting in cognitive disorders, in which central cholinergic projections are important for cognitive function. In Alzheimer disease, cholinergic neurons have been shown to degenerate. This suggests that NGF may be used to pharmacologically counteract cholinergic degeneration and/or induce terminal sprouting in Alzheimer disease. Data from animal studies, as well as from the author's recent clinical trial, in which NGF was infused to the lateral ventricle in patients with Alzheimer disease, will be presented. Effects of NGF on cognition, as well as issues regarding dosage, side effects, and alternative ways of administering NGF, will be discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10850728     DOI: 10.1097/00002093-200000001-00006

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  9 in total

1.  Molecular simulation of the binding of nerve growth factor peptide mimics to the receptor tyrosine kinase A.

Authors:  Marco Berrera; Antonino Cattaneo; Paolo Carloni
Journal:  Biophys J       Date:  2006-06-23       Impact factor: 4.033

2.  Effects of Gingko Extract (EGb761) on oxidative damage under different conditions of serum supply.

Authors:  Chun Shi; Zhibing Yao; Jie Xu; David T Yew
Journal:  J Bioenerg Biomembr       Date:  2009-02-11       Impact factor: 2.945

Review 3.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

Review 4.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

Review 5.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Green tea polyphenols potentiate the action of nerve growth factor to induce neuritogenesis: possible role of reactive oxygen species.

Authors:  Usha Gundimeda; Thomas H McNeill; Jason E Schiffman; David R Hinton; Rayudu Gopalakrishna
Journal:  J Neurosci Res       Date:  2010-10-08       Impact factor: 4.164

7.  Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the Göttingen minipig basal forebrain.

Authors:  Lone Fjord-Larsen; Philip Kusk; Jens Tornøe; Bengt Juliusson; Malene Torp; Carsten R Bjarkam; Mette S Nielsen; Aase Handberg; Jens Christian H Sørensen; Lars U Wahlberg
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

Review 8.  Cerebrolysin: a review of its use in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  The Traditional Japanese Herbal Medicine Hachimijiogan Elicits Neurite Outgrowth Effects in PC12 Cells and Improves Cognitive in AD Model Rats via Phosphorylation of CREB.

Authors:  Kaori Kubota; Haruka Fukue; Hitomi Sato; Kana Hashimoto; Aya Fujikane; Hiroshi Moriyama; Takuya Watanabe; Shutaro Katsurabayashi; Mosaburo Kainuma; Katsunori Iwasaki
Journal:  Front Pharmacol       Date:  2017-11-21       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.